Gross margin
64.0% Fiscal year 2025
Rank 70 of 100: higher than 70% of 153 peers (All). strong.
Rank 38 of 100: higher than 38% of 20 peers (Sector). medium.
Median Health Care: 66.6%
Share of revenue left after the direct cost of the products sold.
About the company
Stryker is a major US medical technology company. It makes hip and knee replacements, surgical robots, surgical instruments, hospital beds and neurosurgery products. Customers are hospitals in many countries. As of Oct 11, 2026
Fact sheet (from the annual report) Medical instruments · Portage, USA
Stryker offers products and services in the areas MedSurg, Neurotechnology and Orthopaedics. MedSurg and Neurotechnology comprises surgical equipment and navigation systems, endoscopy, patient handling and emergency care as well as products for stroke, venous thromboembolism and neurosurgery. Orthopaedics mainly supplies implants for hip, knee, shoulder and ankle replacement as well as for trauma and extremities surgery, plus the Mako robotic system. The products are sold through its own subsidiaries as well as dealers and distributors, mostly directly to physicians, hospitals and other facilities.
Automatically summarized from SEC annual report (10-K, filed Feb 11, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026
Price performance at a glance
Last 30 trading days
- Today −1.5%
- 7 days −1.0%
- 30 days +10.7%
- 1 year −21.5%
Day range (last trading day)
−0.8%Price at 38% of the range+1.4%
52-week range
−11.4%Price at 28% of the range+29.2%
- Distance from the all-time high
- −25.8%
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Pullback in trend · Analysis method
This method currently detects no pattern for SYK. The check runs daily after the close.
You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing
What does the pattern show?
What is this? In an intact uptrend (price above the 200-day line, 50-day line rising), the price pulls back to the 50-day line after a rise and closes back above it.
This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and marginStryker Corporation · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 11, 2026.
Quality checks
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
Quality
Profitability, consistency, balance sheet
7 of 8 criteria met
Growth
Revenue and earnings per share
7 of 7 criteria met
Dividend
Level, consistency, coverage
7 of 7 criteria met
Financial strength
Piotroski, debt, liquidity
5 of 6 criteria met
Quality 7 of 8 met
- met: Gross margin above 40% 64.0%
- met: Operating margin above 15% 19.5%
- met: Net margin above 10% 12.9%
- not met: Return on equity above 15% 14.5%
- met: Free cash flow margin above 10% 17.1%
- met: Profit in each of the last 5 fiscal years 5 of 5
- met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
- met: Equity ratio above 30% 46.9%
Operating margin
19.5% Fiscal year 2025
Rank 58 of 100: higher than 58% of 192 peers (All). medium.
Rank 63 of 100: higher than 63% of 20 peers (Sector). medium.
Median Health Care: 18.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
12.9% Fiscal year 2025
Rank 48 of 100: higher than 48% of 237 peers (All). medium.
Rank 44 of 100: higher than 44% of 26 peers (Sector). medium.
Median Health Care: 13.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
14.5% Fiscal year 2025
Rank 46 of 100: higher than 46% of 218 peers (All). medium.
Rank 60 of 100: higher than 60% of 21 peers (Sector). medium.
Median Health Care: 14.3%
Net income divided by equity at fiscal year end.
Return on assets
6.8% Fiscal year 2025 (total assets at year end)
Rank 57 of 100: higher than 57% of 238 peers (All). medium.
Rank 52 of 100: higher than 52% of 26 peers (Sector). medium.
Median Health Care: 6.4%
Net income divided by total assets at fiscal year end.
Equity ratio
46.9% Fiscal year 2025
Rank 64 of 100: higher than 64% of 239 peers (All). medium.
Rank 63 of 100: higher than 63% of 26 peers (Sector). medium.
Median Health Care: 38.5%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
17.1% Fiscal year 2025
Rank 59 of 100: higher than 59% of 213 peers (All). medium.
Rank 58 of 100: higher than 58% of 25 peers (Sector). medium.
Median Health Care: 14.9%
Free cash flow divided by revenue.
Free cash flow
4.3B USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 7 of 7 met
- met: Over 3 years, revenue grew by more than 5% per year +10.8%
- met: Over 5 years, revenue grew by more than 5% per year +11.8%
- met: Over 10 years, revenue grew by more than 5% per year +9.7%
- met: Over 3 years, EPS grew by more than 5% per year +10.8%
- met: Over 5 years, EPS grew by more than 5% per year +14.9%
- met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
- met: Revenue rose in the last fiscal year +11.2%
Revenue growth 3 years
+10.8% per year
Rank 59 of 100: higher than 59% of 230 peers (All). medium.
Rank 70 of 100: higher than 70% of 25 peers (Sector). strong.
Median Health Care: +5.6%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+11.8% per year
Rank 53 of 100: higher than 53% of 217 peers (All). medium.
Rank 74 of 100: higher than 74% of 25 peers (Sector). strong.
Median Health Care: +8.5%
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+9.7% per year
Rank 61 of 100: higher than 61% of 157 peers (All). medium.
Rank 39 of 100: higher than 39% of 19 peers (Sector). medium.
Median Health Care: +10.1%
Average growth per year over 10 fiscal years.
EPS growth 3 years
+10.8% per year
Rank 49 of 100: higher than 49% of 157 peers (All). medium.
Rank 70 of 100: higher than 70% of 22 peers (Sector). strong.
Median Health Care: +5.5%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 5 years
+14.9% per year
Rank 54 of 100: higher than 54% of 146 peers (All). medium.
Rank 68 of 100: higher than 68% of 20 peers (Sector). strong.
Median Health Care: +7.0%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 10 years
+8.3% per year
Rank 43 of 100: higher than 43% of 140 peers (All). medium.
Rank 53 of 100: higher than 53% of 20 peers (Sector). medium.
Median Health Care: +8.3%
Growth of earnings per share per year, adjusted for stock splits.
Dividend 7 of 7 met
- met: Pays a dividend 3.40 USD
- met: Payout ratio at most 60% of earnings 40%
- met: Dividend paid in each of the last 5 fiscal years 5 of 5
- met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
- met: Dividend per share higher than 5 years ago +7.6%
- met: Free cash flow per share covers the dividend 3.3x
- met: Dividends paid over the last 5 years covered by free cash flow 36% of free cash flow
Payout ratio
40% Fiscal year 2025
Dividend per share divided by earnings per share.
Dividend growth 5 years
+7.6% per year
Rank 43 of 100: higher than 43% of 118 peers (All). medium.
Rank 47 of 100: higher than 47% of 16 peers (Sector). medium.
Median Health Care: +7.8%
Growth of the dividend per share per year.
Free cash flow coverage
3.3x Fiscal year 2025
Free cash flow per share divided by dividend per share. From 1x the dividend is covered.
Financial strength 5 of 6 met
- not met: Piotroski F-Score at least 7 of 9 6 of 9
- met: Long-term debt no higher than equity 0.66
- met: Current assets cover current liabilities 1.89
- met: Positive equity 22.4B USD
- met: In 5 years, share count up by at most 5% +1.6%
- met: Free cash flow positive in the last fiscal year 4.3B USD
Piotroski F-Score
6 of 9 Fiscal year 2025
Rank 45 of 100: higher than 45% of 134 peers (All). medium.
Rank 32 of 100: higher than 32% of 19 peers (Sector). weak.
Median Health Care: 7.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
0.66 at fiscal year end
Rank 48 of 100: lower than 48% of 199 peers (All). medium.
Rank 64 of 100: lower than 64% of 18 peers (Sector). medium.
Median Health Care: 0.72
Long-term financial debt divided by equity.
Liquidity (current ratio)
1.89 at fiscal year end
Rank 66 of 100: higher than 66% of 215 peers (All). medium.
Rank 67 of 100: higher than 67% of 26 peers (Sector). strong.
Median Health Care: 1.56
Current assets divided by current liabilities.
Change in share count
+1.6% in 5 years
Rank 37 of 100: lower than 37% of 199 peers (All). medium.
Rank 15 of 100: lower than 15% of 24 peers (Sector). weak.
Median Health Care: −2.7%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
- met: Profit in the last fiscal year (positive return on assets)
- met: Positive operating cash flow
- met: Return on assets higher than the prior year
- met: Operating cash flow higher than net income
- not met: Long-term debt relative to total assets fell
- not met: Liquidity (current assets / current liabilities) rose
- not met: No additional shares (diluted share count did not rise)
- met: Gross margin higher than the prior year
- met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
- Light green: Revenue grew over 5 years (+11.8% per year), at least as fast as the sector median.
- Light green: Net income (total) grew over 5 years (+15.2% per year), at least as fast as the sector median; per share +14.9% per year.
- Light green: Net margin 12.9%, above the sector median (12.9%).
- Light green: Debt not higher than usual in the sector.
- Light green: Profit in each of the last 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 11.3B USD · Net income 1.6B USD · Net margin 14.5%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 12.4B USD · Net income 1.0B USD · Net margin 8.2%
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 13.6B USD · Net income 3.6B USD · Net margin 26.1%
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 14.9B USD · Net income 2.1B USD · Net margin 14.0%
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 14.4B USD · Net income 1.6B USD · Net margin 11.1%
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 17.1B USD · Net income 2.0B USD · Net margin 11.7%
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 18.4B USD · Net income 2.4B USD · Net margin 12.8%
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 20.5B USD · Net income 3.2B USD · Net margin 15.4%
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 22.6B USD · Net income 3.0B USD · Net margin 13.2%
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 25.1B USD · Net income 3.2B USD · Net margin 12.9%
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 4.9B USD · Net income 692.0M USD · Net margin 14.1%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 5.8B USD · Net income 1.1B USD · Net margin 19.7%
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 5.2B USD · Net income 788.0M USD · Net margin 15.0%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 5.4B USD · Net income 825.0M USD · Net margin 15.2%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 5.5B USD · Net income 834.0M USD · Net margin 15.2%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 6.4B USD · Net income 546.0M USD · Net margin 8.5%
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 5.9B USD · Net income 654.0M USD · Net margin 11.1%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 6.0B USD · Net income 884.0M USD · Net margin 14.7%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 6.1B USD · Net income 859.0M USD · Net margin 14.2%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 7.2B USD · Net income 849.0M USD · Net margin 11.8%
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 6.0B USD · Net income 745.0M USD · Net margin 12.4%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 6.6B USD · Net income 1.3B USD · Net margin 19.4%
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share 4.35 USD
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share 2.68 USD
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 9.34 USD
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 5.48 USD
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 4.20 USD
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 5.21 USD
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 6.17 USD
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 8.25 USD
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share 7.76 USD
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 8.40 USD
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Earnings per share 1.80 USD
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Earnings per share 2.98 USD
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share 2.05 USD
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share 2.14 USD
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Earnings per share 2.16 USD
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Earnings per share 1.41 USD
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Earnings per share 1.69 USD
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Earnings per share 2.29 USD
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Earnings per share 2.22 USD
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share 2.20 USD
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share 1.93 USD
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share 3.30 USD
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Dividend per share 1.57 USD · Payout ratio 36.0%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Dividend per share not available · Payout ratio not available
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Dividend per share not available · Payout ratio not available
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Dividend per share not available · Payout ratio not available
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Dividend per share not available · Payout ratio not available
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Dividend per share not available · Payout ratio not available
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Dividend per share not available · Payout ratio not available
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Dividend per share not available · Payout ratio not available
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Dividend per share not available · Payout ratio not available
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Dividend per share not available · Payout ratio not available
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Dividend per share 0.75 USD · Payout ratio 41.7%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Dividend per share 0.80 USD · Payout ratio 26.8%
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Dividend per share 0.80 USD · Payout ratio 39.0%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Dividend per share 0.80 USD · Payout ratio 37.4%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Dividend per share 0.80 USD · Payout ratio 37.0%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Dividend per share 0.84 USD · Payout ratio 59.6%
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Dividend per share 0.84 USD · Payout ratio 49.7%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Dividend per share 0.84 USD · Payout ratio 36.7%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Dividend per share 0.84 USD · Payout ratio 37.8%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Dividend per share 0.88 USD · Payout ratio 40.0%
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Dividend per share 0.88 USD · Payout ratio 45.6%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Dividend per share 0.88 USD · Payout ratio 26.7%
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 25.1B USD · Net income 3.2B USD · Net margin 12.9%
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 64.0 USD gross profit, 19.5 USD operating income and 12.9 USD net income remained.
Money flow as a table
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 25.1B USD | 100.0% |
| Gross profit | 16.1B USD | 64.0% |
| Cost of revenue | 9.1B USD | 36.0% |
| Operating income | 4.9B USD | 19.5% |
| Research & development | 1.6B USD | 6.5% |
| Other operating expenses | 9.6B USD | 38.0% |
| Net income | 3.2B USD | 12.9% |
| Interest expense | 607.0M USD | 2.4% |
| Taxes & other (net) | 1.0B USD | 4.1% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Margins
The operating margin rose in 5 years from 15.5% to 19.5%.
Gross marginOperating marginNet margin- Fiscal year 2016: Gross margin 66.2% · Operating margin 19.1% · Net margin 14.5%
- Fiscal year 2017: Gross margin 65.7% · Operating margin 18.4% · Net margin 8.2%
- Fiscal year 2018: Gross margin 65.7% · Operating margin 18.7% · Net margin 26.1%
- Fiscal year 2019: Gross margin 65.1% · Operating margin 18.2% · Net margin 14.0%
- Fiscal year 2020: Gross margin 63.1% · Operating margin 15.5% · Net margin 11.1%
- Fiscal year 2021: Gross margin 64.1% · Operating margin 15.1% · Net margin 11.7%
- Fiscal year 2022: Gross margin 62.8% · Operating margin 15.4% · Net margin 12.8%
- Fiscal year 2023: Gross margin 63.7% · Operating margin 19.0% · Net margin 15.4%
- Fiscal year 2024: Gross margin 63.9% · Operating margin 16.3% · Net margin 13.2%
- Fiscal year 2025: Gross margin 64.0% · Operating margin 19.5% · Net margin 12.9%
Returns
Return on equity rose in 5 years from 12.2% to 14.5%.
Return on equityReturn on assets- Fiscal year 2016: Return on equity 17.2% · Return on assets 8.1%
- Fiscal year 2017: Return on equity 10.2% · Return on assets 4.6%
- Fiscal year 2018: Return on equity 30.3% · Return on assets 13.0%
- Fiscal year 2019: Return on equity 16.3% · Return on assets 6.9%
- Fiscal year 2020: Return on equity 12.2% · Return on assets 4.7%
- Fiscal year 2021: Return on equity 13.4% · Return on assets 5.8%
- Fiscal year 2022: Return on equity 14.2% · Return on assets 6.4%
- Fiscal year 2023: Return on equity 17.0% · Return on assets 7.9%
- Fiscal year 2024: Return on equity 14.5% · Return on assets 7.0%
- Fiscal year 2025: Return on equity 14.5% · Return on assets 6.8%
Equity and long-term debt
The equity ratio rose in 5 years from 38.1% to 46.9%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.- Fiscal year 2016: Equity 9.6B USD · Long-term debt 6.7B USD
- Fiscal year 2017: Equity 10.0B USD · Long-term debt 6.6B USD
- Fiscal year 2018: Equity 11.7B USD · Long-term debt 8.5B USD
- Fiscal year 2019: Equity 12.8B USD · Long-term debt 10.2B USD
- Fiscal year 2020: Equity 13.1B USD · Long-term debt 13.2B USD
- Fiscal year 2021: Equity 14.9B USD · Long-term debt 12.5B USD
- Fiscal year 2022: Equity 16.6B USD · Long-term debt 11.9B USD
- Fiscal year 2023: Equity 18.6B USD · Long-term debt 10.9B USD
- Fiscal year 2024: Equity 20.6B USD · Long-term debt 12.2B USD
- Fiscal year 2025: Equity 22.4B USD · Long-term debt 14.9B USD
Liquidity (current ratio)
The current ratio stayed roughly the same in 5 years (1.89).
Current ratio- Fiscal year 2016: Current ratio 2.50
- Fiscal year 2017: Current ratio 2.29
- Fiscal year 2018: Current ratio 2.02
- Fiscal year 2019: Current ratio 2.58
- Fiscal year 2020: Current ratio 1.93
- Fiscal year 2021: Current ratio 2.20
- Fiscal year 2022: Current ratio 1.63
- Fiscal year 2023: Current ratio 1.58
- Fiscal year 2024: Current ratio 1.95
- Fiscal year 2025: Current ratio 1.89
Cash flow
Free cash flow rose in 5 years from 2.8B USD to 4.3B USD.
Operating cash flowCapital expenditureFree cash flow in USD- Fiscal year 2016: Operating cash flow 1.8B USD · Capital expenditure 490.0M USD · Free cash flow 1.3B USD
- Fiscal year 2017: Operating cash flow 1.6B USD · Capital expenditure 598.0M USD · Free cash flow 961.0M USD
- Fiscal year 2018: Operating cash flow 2.6B USD · Capital expenditure 572.0M USD · Free cash flow 2.0B USD
- Fiscal year 2019: Operating cash flow 2.2B USD · Capital expenditure 649.0M USD · Free cash flow 1.5B USD
- Fiscal year 2020: Operating cash flow 3.3B USD · Capital expenditure 487.0M USD · Free cash flow 2.8B USD
- Fiscal year 2021: Operating cash flow 3.3B USD · Capital expenditure 525.0M USD · Free cash flow 2.7B USD
- Fiscal year 2022: Operating cash flow 2.6B USD · Capital expenditure 588.0M USD · Free cash flow 2.0B USD
- Fiscal year 2023: Operating cash flow 3.7B USD · Capital expenditure 575.0M USD · Free cash flow 3.1B USD
- Fiscal year 2024: Operating cash flow 4.2B USD · Capital expenditure 755.0M USD · Free cash flow 3.5B USD
- Fiscal year 2025: Operating cash flow 5.0B USD · Capital expenditure 761.0M USD · Free cash flow 4.3B USD
Share count
The share count rose in 5 years by 1.6% – more new shares were issued than repurchased (dilution).
Diluted share count- Fiscal year 2016: Diluted share count 378.5M
- Fiscal year 2017: Diluted share count 380.1M
- Fiscal year 2018: Diluted share count 380.3M
- Fiscal year 2019: Diluted share count 379.9M
- Fiscal year 2020: Diluted share count 380.3M
- Fiscal year 2021: Diluted share count 382.3M
- Fiscal year 2022: Diluted share count 382.2M
- Fiscal year 2023: Diluted share count 383.7M
- Fiscal year 2024: Diluted share count 385.6M
- Fiscal year 2025: Diluted share count 386.5M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
- Dividend per share
- 3.40 USD · Fiscal year 2025
- Dividend growth per year
- 3 y +6.2%5 y +7.6%10 y +9.2%
- Years without a cut
- at least 10 as far as the data goes
- Payout ratio
- of earnings 40% of free cash flow 30%
- To shareholders (5 years)
- 5.6B USD 0% through repurchases
- Share count over 5 years
- +1.6% more shares – dilution
Dividend per share
The dividend per share rose in 5 years from 2.36 USD to 3.40 USD.
Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.- Fiscal year 2016: Dividend per share 1.57 USD
- Fiscal year 2017: Dividend per share 1.75 USD
- Fiscal year 2018: Dividend per share 1.93 USD
- Fiscal year 2019: Dividend per share 2.14 USD
- Fiscal year 2020: Dividend per share 2.36 USD
- Fiscal year 2021: Dividend per share 2.59 USD
- Fiscal year 2022: Dividend per share 2.84 USD
- Fiscal year 2023: Dividend per share 3.05 USD
- Fiscal year 2024: Dividend per share 3.24 USD
- Fiscal year 2025: Dividend per share 3.40 USD
Payout ratios
The payout ratio fell in 5 years from 56.1% to 40.5%.
Payout ratio (earnings)Payout ratio (free cash flow)- Fiscal year 2016: Payout ratio (earnings) 36.0% · Payout ratio (free cash flow) 43.0%
- Fiscal year 2017: Payout ratio (earnings) 65.1% · Payout ratio (free cash flow) 66.2%
- Fiscal year 2018: Payout ratio (earnings) 20.7% · Payout ratio (free cash flow) 34.5%
- Fiscal year 2019: Payout ratio (earnings) 39.0% · Payout ratio (free cash flow) 50.5%
- Fiscal year 2020: Payout ratio (earnings) 56.1% · Payout ratio (free cash flow) 30.9%
- Fiscal year 2021: Payout ratio (earnings) 49.6% · Payout ratio (free cash flow) 34.7%
- Fiscal year 2022: Payout ratio (earnings) 45.9% · Payout ratio (free cash flow) 51.6%
- Fiscal year 2023: Payout ratio (earnings) 37.0% · Payout ratio (free cash flow) 36.3%
- Fiscal year 2024: Payout ratio (earnings) 41.8% · Payout ratio (free cash flow) 35.0%
- Fiscal year 2025: Payout ratio (earnings) 40.5% · Payout ratio (free cash flow) 30.0%
What goes back to shareholders
Over 5 years, 5.6B USD went back to shareholders as dividends. That is 36% of the free cash flow of those years.
Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD- Fiscal year 2016: Dividends paid 568.0M USD · Share repurchases 13.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
- Fiscal year 2017: Dividends paid 636.0M USD · Share repurchases 230.0M USD · New shares issued (including employee plans) not available · Free cash flow 961.0M USD
- Fiscal year 2018: Dividends paid 703.0M USD · Share repurchases 300.0M USD · New shares issued (including employee plans) not available · Free cash flow 2.0B USD
- Fiscal year 2019: Dividends paid 778.0M USD · Share repurchases 307.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.5B USD
- Fiscal year 2020: Dividends paid 863.0M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 2.8B USD
- Fiscal year 2021: Dividends paid 950.0M USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 2.7B USD
- Fiscal year 2022: Dividends paid 1.1B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 2.0B USD
- Fiscal year 2023: Dividends paid 1.1B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 3.1B USD
- Fiscal year 2024: Dividends paid 1.2B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 3.5B USD
- Fiscal year 2025: Dividends paid 1.3B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 4.3B USD
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Sector comparison
Stryker Corporation next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| BMY Bristol Myers Squibb | 48.2B USD | +2.5% | 71.1% | – | 14.6% | 38.2% | 20.5% | 26.7% | 8/9 |
| TMO Thermo Fisher Scientific | 44.6B USD | +6.7% | – | 17.4% | 15.0% | 12.6% | 48.4% | 14.1% | – |
| ABT Abbott Laboratories | 44.3B USD | +5.1% | 56.4% | 18.2% | 14.7% | 12.5% | 60.1% | 16.7% | 6/9 |
| AMGN Amgen | 36.8B USD | +7.6% | 67.2% | 24.7% | 21.0% | 89.1% | 9.6% | 22.0% | 7/9 |
| MDT Medtronic | 36.4B USD | +3.8% | 65.0% | 17.8% | 13.2% | 9.7% | 53.2% | 14.9% | 7/9 |
| GILD Gilead Sciences | 29.4B USD | +3.6% | 78.8% | 34.0% | 28.9% | 37.5% | 38.5% | 32.1% | 8/9 |
| SYK Stryker Corporation this stock | 25.1B USD | +11.8% | 64.0% | 19.5% | 12.9% | 14.5% | 46.9% | 17.1% | 6/9 |
| DHR Danaher Corporation | 24.6B USD | +2.0% | 59.1% | 19.1% | 14.7% | 6.9% | 62.9% | 21.4% | 7/9 |
| REGN Regeneron Pharmaceuticals | 14.3B USD | +11.0% | – | 24.9% | 31.4% | 14.4% | 77.1% | 28.4% | – |
| Median of the sector 26 symbols | 44.4B USD | +8.5% | 66.6% | 18.0% | 13.9% | 14.3% | 38.5% | 14.9% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+11.8% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 11.8% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+15.2% per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: +14.9% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 15.2% per year on average – at least as fast as the median company in the sector (+7.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net margin
Profit marginThe share of revenue that is left as profit after all costs.Example: Profit €60m on €500m revenue → margin 12%.More in the Academy: Lesson revenue, profit and margin12.9% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue, 12.92 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 11.1%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth0.59 latest balance sheet
Sector Health Care: median 0.66 (49 symbols)
What does this mean? For every 1 USD of equity there is 0.59 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth– Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin10 of 10 fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
All figures as a table
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 25.1B | 3.2B | 12.9% | 8.40 | – | – |
| 2024 | Dec 31, 2024 | 22.6B | 3.0B | 13.2% | 7.76 | – | – |
| 2023 | Dec 31, 2023 | 20.5B | 3.2B | 15.4% | 8.25 | – | – |
| 2022 | Dec 31, 2022 | 18.4B | 2.4B | 12.8% | 6.17 | – | – |
| 2021 | Dec 31, 2021 | 17.1B | 2.0B | 11.7% | 5.21 | – | – |
| 2020 | Dec 31, 2020 | 14.4B | 1.6B | 11.1% | 4.20 | – | – |
| 2019 | Dec 31, 2019 | 14.9B | 2.1B | 14.0% | 5.48 | – | – |
| 2018 | Dec 31, 2018 | 13.6B | 3.6B | 26.1% | 9.34 | – | – |
| 2017 | Dec 31, 2017 | 12.4B | 1.0B | 8.2% | 2.68 | – | – |
| 2016 | Dec 31, 2016 | 11.3B | 1.6B | 14.5% | 4.35 | 1.57 | 36% |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 6.6B | 1.3B | 19.4% | 3.30 | 0.88 | 27% |
| Q1/26 | Mar 31, 2026 | 6.0B | 745.0M | 12.4% | 1.93 | 0.88 | 46% |
| Q4/25 | Dec 31, 2025 | 7.2B | 849.0M | 11.8% | 2.20 | 0.88 | 40% |
| Q3/25 | Sep 30, 2025 | 6.1B | 859.0M | 14.2% | 2.22 | 0.84 | 38% |
| Q2/25 | Jun 30, 2025 | 6.0B | 884.0M | 14.7% | 2.29 | 0.84 | 37% |
| Q1/25 | Mar 31, 2025 | 5.9B | 654.0M | 11.1% | 1.69 | 0.84 | 50% |
| Q4/24 | Dec 31, 2024 | 6.4B | 546.0M | 8.5% | 1.41 | 0.84 | 60% |
| Q3/24 | Sep 30, 2024 | 5.5B | 834.0M | 15.2% | 2.16 | 0.80 | 37% |
| Q2/24 | Jun 30, 2024 | 5.4B | 825.0M | 15.2% | 2.14 | 0.80 | 37% |
| Q1/24 | Mar 31, 2024 | 5.2B | 788.0M | 15.0% | 2.05 | 0.80 | 39% |
| Q4/23 | Dec 31, 2023 | 5.8B | 1.1B | 19.7% | 2.98 | 0.80 | 27% |
| Q3/23 | Sep 30, 2023 | 4.9B | 692.0M | 14.1% | 1.80 | 0.75 | 42% |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $118.2M3 people | −$118.2M |
| 6 months | $00 people | $218.9M5 people | −$218.9M |
| 12 months | $00 people | $586.1M8 people | −$586.1M |
Latest transactions
- Aug 21, 2026 Crotty Dylan Bram Officer Open-market sale 441 shares · $144.9K · SEC
- Aug 19, 2026 Stryker Ronda E Director Open-market sale 805 shares · $276.5K · SEC
- Aug 19, 2026 Stryker Ronda E Director Open-market sale 3,852 shares · $1.3M · SEC
- Aug 19, 2026 Stryker Ronda E Director Open-market sale 3,274 shares · $1.1M · SEC
- Aug 19, 2026 Stryker Ronda E Director Open-market sale 16,612 shares · $5.7M · SEC
- Aug 19, 2026 Stryker Ronda E Director Open-market sale 10,812 shares · $3.7M · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score -15
Price vs. EMA 50+15
Price vs. EMA 200-15
EMA 50 vs. EMA 200-20
ADX (trend strength)+0
Highs and lows+20
Relative strength-15
Volatility and trend strength
ADX 14 (trend strength)19.3
Rel. strength 60 d−12.5%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
More stocks from Health Care
News
No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.
Posts
No posts on SYK yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules